Moderna’s stock surged after the company, in partnership with Merck, announced positive Phase 3 results for its personalized mRNA cancer vaccine in melanoma. The treatment significantly delayed cancer recurrence and spread, and is now being tested against other cancers.
Moderna announced on Wednesday that its individualized mRNA cancer vaccine, developed jointly with Merck, succeeded in a Phase 3 trial for advanced melanoma. The vaccine, tailored to each patient’s tumor mutations, significantly improved recurrence-free survival. The results caused Moderna’s stock to nearly double. The company is already testing the platform in other cancers including lung and pancreatic. The breakthrough marks a major milestone in personalized oncology.
4 developments
Source and signal
- Open-source intake